文献速递慢性静脉疾病

InVera输注装置治疗隐静脉功能不全的12个月试点研究结果

A pilot study of the InVera Infusion Device: Twelve-month outcomes in the treatment of incompetent saphenous veins.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-10-19

这项单中心前瞻性试点研究纳入10例原发性症状性轴性反流患者,使用InVera输注装置进行化学消融。技术成功率为100%,无器械相关不良事件,12个月时rVCSS和HASTI评分均显著改善,90%患者超声显示异常反流消除及完全或部分闭塞。

要点

  • InVera装置行非热非肿胀化学消融技术成功率达100%。
  • 随访期间无器械相关不良事件,包括无深静脉血栓形成。
  • 12个月时rVCSS与HASTI评分较基线均显著下降(校正P=0.03)。

核心结论

  • InVera输注装置作为隐静脉功能不全的硬化剂输送工具安全有效,12个月解剖、临床及患者报告结局良好。

研究设计与样本

  • 单中心前瞻性试点研究,纳入10例原发性症状性轴性反流并接受InVera装置化学消融的患者。
  • 主要结局为技术成功、不良事件、rVCSS、基于HASTI问卷的患者报告结局及基线至术后12个月的多时间点超声解剖成功率。
  • 基线与12个月rVCSS比较采用配对t检验,HASTI结果比较采用Wilcoxon符号秩检验。

主要发现

  • 技术成功率为100%。
  • 随访期间无器械相关不良事件或严重不良事件,包括无深静脉血栓形成记录。
  • 临床评估的rVCSS和患者报告的HASTI评分从基线至12个月均显示统计学显著下降(校正P=0.03)。
  • 12个月超声解剖评估显示90%患者异常反流消除及完全或部分闭塞。

临床怎么用

  • 该装置可在非热非肿胀化学消融中用于输送硬化剂,作为隐静脉功能不全管理的一种选择。
  • 术后12个月内可通过rVCSS、HASTI问卷和超声评估反流消除及静脉闭塞情况。

局限性

  • 试点研究样本量小(10例),单中心设计,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The InVera Infusion Device is a novel catheter designed for the delivery of sclerosant agents during non-thermal, non-tumescent (NTNT) ablation of incompetent superficial truncal veins of the lower extremity. This device pilot study aimed to evaluate the technical success, safety, and 12-month clinical outcome. METHODS: A single-center, prospective pilot study enrolled 10 patients with primary symptomatic axial reflux who underwent chemical ablation procedures with sclerosant delivery using the InVera Infusion Device. Primary outcomes assessed were technical procedural success, adverse events, Revised Venous Clinical Severity Score (rVCSS), patient-reported outcomes (PROs) based on a HASTI (Heaviness, Achiness, Swelling, Throbbing, Itching) symptom questionnaire and anatomical success rates from duplex ultrasound examination at baseline, 1 week, 8 weeks, 3, 6, and 12 months post procedure. Baseline and 12 months post procedure were compared for both the rVCSS and the HASTI results using a paired t-test and a Wilcoxon signed-rank test respectively RESULTS: Technical procedural success was 100%. There were no device-related adverse events or serious adverse events including no deep vein thrombosis recorded throughout the follow-up period. Clinician assessed rVCSS and patient reported HASTI scores both showed statistically significant reductions from baseline to 12 months (adjusted p = 0.03 for both). Ultrasound-based anatomical assessment at 12 months demonstrated elimination of abnormal reflux and complete or partial occlusion in 90% of patients. CONCLUSIONS: The InVera Infusion device provides a safe and effective technique for the delivery of sclerosant agents as part of the management of incompetent saphenous veins, demonstrating favorable 12-month anatomical, clinical and patient reported outcomes in this pilot cohort.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Bihari I, Madden S, Phelan N, et al. A pilot study of the InVera Infusion Device: Twelve-month outcomes in the treatment of incompetent saphenous veins. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42896734. doi:10.1016/j.jvsv.2026.102642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。